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Inﬂammation plays a pivotal role in all stages of atherosclerosis. Numerous inﬂammatory, lipid, and cytokines markers have been
associated with coronary artery disease (CAD) risk but data directly comparing their predictive value are limited. Studies were
carried to elucidate the role of high-sensitivity C-reactive protein (hsCRP), other inﬂammatory as well as lipid markers and their
associations. Among 1021 subjects, comprising 774 CAD aﬀected members from Indian Atherosclerosis Research Study (IARS),
plasma hsCRP levels showed strong correlation with inﬂammatory markers, namely, IL6 (r = .373; P =<. 0001), sPLA2 (r = .544;
P =<. 0001) as also with ﬁbrinogen (r = .579; P =<. 0001). Levels of hsCRP were higher among subjects aﬀected by CAD
who suﬀered a repeat coronary event as compared to those who remained event free and subjects in the top quartile of hsCRP
(> 3.58mg/L)werefoundtohaveafourfoldhigherrisk.Inconclusion,hsCRPappearstobeanindependentpredictorofrecurrent
CAD events in Asian Indian population.
1.Introduction
Inﬂammation plays a major role in the pathophysiology
of atherosclerosis [1–4]. Many novel inﬂammatory markers
have been investigated in an eﬀort to improve the risk
predictiveabilityoffuturecoronaryarterydisease(CAD)[5–
8]. With the exception of high-sensitivity C-reactive protein
(hsCRP), no inﬂammatory marker evaluated thus far has
demonstrated consistent and independent value towards
prediction of future CAD risk. High sensitive CRP has
been advocated as the most attractive candidate novel bio-
marker for inclusion in existing risk prediction models,
primarily due to its stability, low diurnal variation, and ease
of measurement [9]. hsCRP has been accepted to provide
additional value to the Framingham risk scoring system
devised for future 10yr CAD risk prediction, even in the
presence of conventional CAD risk factors [10–13].
CRP is an acute-phase reactant belonging to the pen-
traxin family. It is almost exclusively produced in the
hepatocytes under the control of cytokines [14], although
extrahepatic sites of CRP synthesis have been reported [15–
18]. The major functions of CRP include binding to various
ligands on damaged tissue followed by propagation of both
anti- and proinﬂammatory eﬀects [19–21]. Recent evidence
indicates that CRP plays an active role in atherosclerosis
[22, 23]. There is general consensus that individuals in the
topquartileofCRPhaveatwo-tothree-foldhigherriskofan
incident as well as future coronary event compared to those
inthebottomquartile[24].However,thereisongoingdebate
on the potential of plasma CRP to predict future coronary
risk over and above that of established CAD risk factors. The
existing reports are contradictory [6, 12, 24–35]. Signiﬁcant
race-based diﬀerences in CRP levels have been reported.
Considering the prevalent lacunae in current knowledge,2 International Journal of Vascular Medicine
more so with respect to the Asian Indian population, this
study was designed to assess the value of hsCRP in predicting
future CAD in a cohort of high-risk Indians residing in the
Indian subcontinent.
2. Methods
The Indian Atherosclerosis Research Study (IARS) is an
ongoing, family-based, epidemiological study initiated in
2004 to investigate the prevalent genetic, traditional, and
environmental factors associated with CAD in a cohort
of Asian Indians in their home country. Novel biomarker
discovery is one of the many speciﬁc objectives of this
large-scale prospective study. The families in the IARS were
enrolled from two cities: Bangalore in south India and
Mumbai in western India. Subjects were recruited through
a proband treated for CAD and its complications. A proband
waseligibleforrecruitmentwhenhewasolderthan60(men)
or 65 (women) years at onset of CAD. This wasdone in order
to identify families with early onset CAD. All probands had
a positive family history of CAD/CVD. We deﬁned CAD-
aﬀected individuals as those who had documented evidence
ofanacutecoronarysyndromewithorwithoutangiographic
evidence of CAD and/or had undergone revascularization
procedures. Probands’ family members (both aﬀected and
unaﬀected by CVD) were subsequently enrolled into the
study, provided they were aged 18 years or above at the
time of recruitment. There was no upper age limit for any
of the nonproband recruits. Subjects with present or past
major illnesses such as cancer, cardiomyopathy, rheumatic
heartdisease,liverorrenaldiseaseandconcomitantinfection
were excluded from the study. All participants gave their
written informed consent to participate in the study, which
was approved by the local ethics committee.
A detailed case record form containing information on
demographics, anthropometry, and medical history of dia-
betes, hypertension, and CVD was completed for all partici-
pants. A general physical examination was performed, along
with measurement of vital parameters. Relevant information
was obtained by personal interviews with subjects and from
medical records. Prevalence of diabetes, hypertension, and
CVD was ascertained based on self-report of physician’s
diagnosis and/or use of prescription medications along with
medical records of diagnosis and therapy. Patients were
followed up via telephone calls once every year. This follow-
up data was collected during conversation with the patients
themselves and all clinical data, including current medical
therapy was judiciously recorded.
2.1. Biomarker Assays. All the biomarker assays were per-
formed in accordance to standard protocols at the central
research facility of the Thrombosis Research Institute (TRI)
at Bangalore. Serum total cholesterol and triglyceride were
estimated by standard enzymatic analysis using reagents,
standards and controls from Randox Laboratories Ltd.
(Antrim, UK). The concentrations of high-density lipopro-
tein (HDL)-cholesterol were estimated after precipitation of
non-HDL fractions with a mixture of 2.4 mmol/L phos-
photungstic acid and 39mmol/L magnesium chloride. The
concentrations of low-density lipoprotein (LDL)-cholesterol
were calculated using the Fridewald formula. Apolipopro-
teins A1 and B100 (Orion Diagnostics, Espoo, Finland) were
estimated by immunoturbidimetry method. Analyses were
carried out on a Cobas-Fara II Clinical Chemistry Autoanal-
yser (F. Hoﬀmann La Roche Ltd., Basel, Switzerland). Three
commercial controls purchased from Randox Laboratories,
one from Orion Diagnostica for apolipoproteins and a
normal human serum pool (NHP) prepared in-house was
run with every batch of assays. The interassay coeﬃcients of
variation (CV) for the commercial controls and NHP ranged
from 4.9% to 7.0% for total cholesterol, 6.1% to 7.7% for
triglyceride, 7.1% to 12.2% for HDL-cholesterol, 3.3% to
5.2% for Lp(a), 9.9% to 14.2% for apolipoprotein A1, and
10.7% to 13.9% for apolipoprotein B100.
Plasmainterleukin(IL)-6levelwasmeasuredbyenzyme-
linked immunosorbent assay (R & D Systems, Minneapolis,
USA); the interassay CV for NHP was 4.3%. Plasma hsCRP
level was measured using the Roche latex Tina quant kit
(Roche Diagnsotics, Basel, Switzerland); the CV of NHP was
7.85%. Levels of secretory phospholipase A2 (sPLA2) were
determined using a sandwich immunometric assay (Cayman
Corporation, Michigan, USA) and the interassay CV of
NHP was 5.37%. Plasma ﬁbrinogen and FVII:C activity were
measured in clotting assays on an Automated Coagulation
Analyser (ACL 300, Instrumentation Laboratory, Milano,
Italy). The reagents, calibrators, and controls were purchased
from IL (Lexington, MA, USA). A commercial control and
pooled normal human plasma (NHP) prepared in-house
from citrate plasma of 30 healthy volunteers were run with
every batch of assay. The interassay CV of the commercial
control and NHP were 5.7% and 5.9%, respectively, for
ﬁbrinogenand5.9%and11.6%,respectively,forFVII:C.The
values of ﬁbrinogen and FVII:C for the commercial control
were within the pre-assigned ranges in every batch of assay.
2.2. Statistical Analysis. All statistical analyses were per-
formed using SPSS version 12. A P-value of less than.05 was
considered statistically signiﬁcant. Variables that showed a
skewed distribution were log transformed before carrying
out further statistical analysis. For the purpose of clarity,
the untransformed mean and standard error of the mean
(SEM) are shown in tables. Diﬀerences between continuous
variables were assessed using Student’s t-test and those
between categorical variables using the chi square test.
Analysis of covariance was also used to test for signiﬁcance
after adjusting for potential confounding variables. Odds
ratios (ORs) and corresponding 95% conﬁdence intervals
(CIs) were calculated using conditional logistic regression
analysis.
3. Results
3.1. Baseline Characteristics of Study Population. At o t a lo f
518 families comprising 2318 individuals were recruited
into Phase I of the IARS. Table 1 describes the baseline
clinical and demographic characteristics of the study pop-
ulation in two groups: CAD-aﬀected individuals who have
suﬀered a coronary event and CAD unaﬀected people atInternational Journal of Vascular Medicine 3
Table 1: Baseline characteristics of study participants.
CAD-patients (n = 774) No CAD (n = 1544) P
Continuous variables, mean (SD)
Age 55.93 (9.36) 40.37 (14.15) <.0001
BMI 25.83 (3.85) 25.67 (4.9) .418
Systolic blood pressure (mmHg) 127.57 (16.74) 122.18 (15.35) <.0001
Diastolic blood pressure (mmHg) 81.53 (8.55) 81 (9.26) .186
Total cholesterol (mg/dL)∗ 155.41 (40.79) 178.27 (40.33) <.0001
Triglycerides (mg/dL)∗ 149.84 (68.86) 131.98 (85.09) <.0001
HDL-cholesterol (mg/dL)∗ 38.75 (9.06) 42.46 (10.6) <.0001
LDL-cholesterol (mg/dL)∗ 86.27 (33.76) 110.18 (34.82) <.0001
Categorical variables, n (%)
Statin 529 (69.2) 44 (2.9) <.0001
Male 630 (81.6) 724 (46.9) <.0001
Female 142 (18.4) 820 (53.1) <.0001
Smoking ··· ··· ···
Never 465 (60.5) 1356 (88.1) ···
Ex-smoker 241 (31.4) 61 (3.96) ···
Occasional 5 (0.7) 25 (1.62) ···
Current smoker 57 (7.4) 98 (6.36) ···
History of
Diabetes 349 (67.9) 529 (57.8) <.0001
Hypertension 378 (73.8) 659 (72.0) .37
Probability values for continuous variables are from 2-sample t-tests and for categorical variables from chi square tests.
∗Log-transformed distribution.
the time of recruitment. Traditional coronary risk factors,
namely, diabetes, hypertension and lipid proﬁle were more
prevalent in the aﬀected group. The lower levels of total
and LDL-cholesterol noted in the CAD-aﬀected group may
be due to the use of statins in over 70% of aﬀected
subjects.
3.2. Comparison of Baseline hsCRP Levels Among CAD-
Aﬀected and Unaﬀected Subjects. Fasting venous blood sam-
ples for biomarker analysis were collected from each one
of the 2318 individuals recruited into phase 1 of the IARS.
hsCRP levels were assayed in 1021 out of the above 2318
collected samples. The selection of samples for the study was
random. Levels of CRP are known to vary across body mass
index (BMI) and gender. However, adjustment for both of
these variables as also for statins did not reveal a signiﬁcant
diﬀerence in the CRP titres between aﬀected and unaﬀected
individuals (Table 2).
Figure 1 categorizes our study population according to
the 2003 Joint American Heart Association and Center
for Disease Control and Prevention (AHA-CDC) (Ref)
guidelines for risk stratiﬁcation of CAD based on CRP titres
as follows: low risk <1mg/L, moderate risk 1–3mg/L, and
high risk >3mg/L. We found no signiﬁcant diﬀerence in
the distribution of subjects in the three risk classes between
the CAD-aﬀected and -unaﬀected subjects (P = .13),
indicating that application of AHA-CDC guidelines for CRP




















Figure 1: Classiﬁcation of subjects based on high-sensitivity
C-reactive protein (hsCRP) levels according to Joint American
Heart Association and Centers for Disease Control and Prevention
guidelines: low risk <1mg/L, moderate risk 1–3mg/L, and high risk
>3mg/L. CAD = coronary artery disease.
3.3. Correlation of hsCRP Levels with Inﬂammatory and Lipid
Markers. The unadjusted and adjusted correlation coeﬃ-
cients for hsCRP are shown in Table 3. hsCRP signiﬁcantly
correlated with IL-6, ﬁbrinogen and sPLA2 levels, after4 International Journal of Vascular Medicine
Table 2: Baseline high-sensitivity C-reactive protein (hsCRP) levels (mg/L).
Male Female
Unaﬀected (n = 281) Aﬀected (n = 321) P Unaﬀected (n = 336) aﬀected (n = 63) P
2.596 ±0.26 2.642 ±0.239 .371∗ 3.303 ±0.228 4.658 ±0.664 .232∗
hsCRP test performed in 1021 samples.


















Figure 2: Distribution of subjects according to high-sensitivity C-
reactive protein (hsCRP) quartiles.
adjustment for age, gender, and BMI. There was moderate
correlation with lipoproteins.
3.4. hsCRP and Risk of Future CAD Events. The study
cohort was periodically followed up over telephone at 1
year intervals. 28.3% of the original cohort was lost during
the follow-up process. Detailed medical information was
obtainedintheremainingcases(71.7%).115individualshad
a new coronary event, irrespective of their baseline disease
status (CAD aﬀected or unaﬀected). CAD-aﬀected subjects
who suﬀered a recurrent event (n = 91) had signiﬁcantly
higher levels of hsCRP than aﬀected subjects who remained
event free (3.98 ± 0.56 versus 2.9 ± 0.17 (mg/L); P = .009).
Over 70% of CAD-aﬀected individuals who suﬀered a repeat
event were in the top quartile of hsCRP titres (Figure 2).
Logistic regression model was used to determine the
ability of hsCRP level to predict future coronary events based
on quartile distribution. There was increasingly signiﬁcant
association of CAD risk with increasing quartiles of hsCRP
levels. The odds of a recurrent coronary event for CAD-
aﬀected individuals in the top quartile of hsCRP was about
four times that of individuals in the other three quartiles
(95% CI 1.45–9.89; P = .006; Model 1, Table 4). After
adjusting for traditional risk factors such as hypertension,
diabetes, gender, age, and BMI, the signiﬁcant association
between hsCRP and risk of repeat coronary events remained
for individuals in the top hsCRP quartile (OR 3.9, 95%CI
1.41–10.8; P = .009; Model 2, Table 4). After additional
adjustment for IL-6, although the OR increased to over
fourfold, the signiﬁcance of the association with future CAD
events was nominal (OR 4.359, 95% CI 1.023–18.573; P =
.047; Model 3, Table 4). When IL-6 was excluded and lipid
variables (total cholesterol, triglycerides, HDL and LDL)
were added into the model, the association between the top
quartile and risk of repeat CAD event persisted (OR 3.106
95% CI 1.07–9.014; P = .037; Model 4 and 5, Table 4.
4. Discussion
The increasing pressure on health resources worldwide, has
led to the emphasis on preventive measures in the battle
against the global pandemic of CAD [36, 37]. Indians are
arguably at a higher risk of developing CAD than other races
and this cannot be explained by traditional risk factors alone
[38–42].Althoughamultitudeoffactorshavebeenmeasured
in the blood of subjects with established atherosclerosis,
only hsCRP has demonstrated an additive value to the risk
assessment of CAD, as endorsed by the Framingham risk
score [9, 11, 26].
The IARS is an ongoing large-scale family-based study
that is investigating novel biomarkers that may contribute
to enhanced risk of CAD in Asian Indians, thereby enabling
the identiﬁcation of high-risk subjects who may beneﬁt from
early intervention. Most published reports of hscRP levels
in Asian Indians have been carried out on subjects living
outside India [43–46]. There are relatively fewer studies in
the Indian population [47, 48] that have reported relatively
small cohorts. Thus, this is the ﬁrst study to determine the
utility of hsCRP as a marker for risk prediction in Asian
Indian subjects with CAD living in their home country.
We did not ﬁnd a signiﬁcant diﬀerence in baseline levels
of hsCRP between CAD aﬀected and unaﬀected subjects
even after adjusting for gender, BMI, and statin therapy.
This may possibly be attributed to therapeutic modiﬁcations
in aﬀected subjects in terms of treatment with inhibitors
of arachidonic acid metabolism (aspirin), PPRγ antagonists
amongst others that are known to possess anti-inﬂammatory
properties in addition to their primary eﬀect. Moreover
lifestyle and diet modiﬁcations play a signiﬁcant role in
overall risk reduction. In our cohort, over 69% of the CAD
aﬀected subjects were on statin therapy while only 2.9% were
on this drug in the unaﬀected group. As expected, hsCRP
levels displayed signiﬁcant correlation with inﬂammatory
markers IL-6, sPLA2, ﬁbrinogen, and neopterin (Table 3).
Interestingly, when we compared the hsCRP levels in CAD-
aﬀected subjects who were followed up for 4 years overInternational Journal of Vascular Medicine 5
Table 3: Correlation of high-sensitivity C-reactive protein (hsCRP) levels with inﬂammatory markers and lipids.
Unadjusted Adjusted†
Characteristics Correlation P Correlation P
sPLA2 (pg/mL)∗ 0.544 <.0001 0.464 <.0001
Interleukin 6 (pg/mL)∗ 0.373 <.0001 0.325 <.0001
Total cholesterol (mg/dL) 0.156 <.0001 0.11 <.0001
HDL (mg/dL) −0.147 <.0001 −0.163 <.0001
LDL (mg/dL) 0.154 <.0001 0.114 <.0001
ApoA1 (g/L) 0.043 .168 0.029 .354
ApoB (g/L) 0.201 <.0001 0.17 <.0001
Triglyceride (mg/dL)∗ 0.208 <.0001 0.161 <.0001
Fibrinogen (g/L) 0.579 <.0001 0.522 <.0001
FVII:C (%) 0.215 <.0001 0.105 .001
∗log-transformed distribution.
†Partial correlations adjusted for age, gender, body mass index, and smoking status.
sPLA2: secretory phospholipase A2; HDL: high-density lipoprotein; LDL: low-density lipoprotein; ApoA1: apolipoprotein A1; ApoB: apoplipoprotein B100;
FVII:C: factor VII coagulant activity.
Table 4: Risk of recurrence of coronary artery disease (CAD) events based on high-sensitivity C-reactive protein (hsCRP) quartiles.
hsCRP quartile
1( <0.7mg/L) 2 (0.71–1.7mg/L) 3 (1.71–3.57mg/L) 4 (>3.58mg/L) P
Model 1 OR (95% CI) 1 1.219 (0.406–3.656) 2.541 (0.954–6.773) 3.793 (1.454–9.898) .019
P .724 .062 .006
Model 2 OR (95% CI) 1 1.194 (0.395–3.614) 2.585 (0.947–7.054) 3.903 (1.411–10.8) .029
P .753 .064 .009
Model 3 OR (95% CI) 1 1.790 (0.406–7.882) 3.363 (0.806–14.04) 4.359 (1.023–18.573) .17
P .441 .096 .047
Model 4 OR (95% CI) 1 1.071 (0.346–3.316) 1.958 (0.695–5.517) 3.204 (1.113–9.227) .093
P .905 .204 .031
Model 5 OR (95% CI) 1 1.115 (0.363–3.429) 1.814 (0.636–5.172) 3.106 (1.07–9.014) .131
P 0849 .265 .037
Model 1: Unadjusted.
Model 2: Adjusted for hypertension, diabetes, gender, age, and body mass index.
Model 3: Additional adjustment for interlukin-6∗
Model 4: Additional adjustment total cholesterol, high-density lipoprotein (HDL) and triglyceride∗.
Model 5: Additional adjustment total cholesterol, HDL, triglyceride∗ and low-density lipoprotein.
∗log-transformed distribution.
OR: odds ratio; CI: conﬁdence interval.
telephoneto assesstheir cardiovascularhealth, wefound that
about 70% of those who developed a recurrent event were
in the top hsCRP quartile (>3.58mg/L). These individuals
have approximately four times higher risk of developing a
recurrent coronary event than those in the bottom quartile
(OR 3.79, 95% CI 1.45–9.89; P = .006). This risk persisted
even after adjusting for traditional risk factors such as
gender, diabetes, hypertension, BMI, and lipids (Table 4,
Model 5), indicating that hsCRP may be an independent
predictor of recurrent CAD event in our population. This
observation agrees with the published studies carried out
in other ethnic groups. Over the last few years, multiple
studies have shown an enhanced risk of recurrent coronary
events with high hsCRP levels in normal healthy populations
and also people within the various spectra of ischemic heart
disease from sub clinical disease through stable angina to
acute coronary syndromes in the presence and absence of
other cardiovascular risk factors [6, 10, 12, 26–28, 31–35].
Our ﬁndings indicate that in the Asian Indian popu-
lation, individuals in the top quartile of hsCRP have an
approximatelythreefoldhigherriskofreinfarction,evenafter
adjustment for traditional CAD risk factors thus implying
that hsCRP may have additional utility for eﬀective risk
stratiﬁcation in this high risk ethnic population. This may
strengthen the case towards a recommendation of routine
measurement of hsCRP along with lipids for improving risk
prediction and identiﬁcation of high-risk individuals. The
AHA-CDC has devised guidelines for the classiﬁcation of
subjects as mild, intermediate and, high risk based on hsCRP
levels. However, this classiﬁcation is based on data obtained6 International Journal of Vascular Medicine
in Caucasian populations, and there is signiﬁcant variation
in hsCRP level based on ethnic origin [43, 44, 49–52]. High-
sensitivity CRP levels are highest among blacks, followed
by South Asians, Mexicans, Hispanics, and Caucasians. In
addition, Asian Indians have a higher predisposition to
diabetes and CVD, resulting in an inherent proinﬂammatory
state[46].Takingallofthesefactsintoaccount,thefeasibility
of application of the AHA-CDC guidelines for classiﬁcation
o fs u b j e c t sn e e d st ob et e s t e db e f o r ei m p l e m e n t a t i o ni na n y
population.Uponclassifyingourstudypopulationaccording
to the AHA-CDC guidelines, we found no signiﬁcant
diﬀerence in the distribution of CAD aﬀected and unaﬀected
subjects across the three AHA-CDC groups (Figure 1). The
unaﬀected subjects were distributed equally among the three
groups. This supports the fact that population-speciﬁc refer-
ence intervals are required for accurate risk stratiﬁcation.
5. Conclusion
Our data indicate that high levels of hsCRP provide addi-
tionalpredictivevaluetothetraditionalriskfactorsinidenti-
ﬁfying CAD-aﬀected subjects who could develop a recurrent
coronary event. Hence, it appears that routine measurement
of hsCRP levels may provide better stratiﬁcation of CAD
risk in this population. However, it is important to carry out
large-scale population-based studies in order to modify and
adapt the existing AHA-CDC guidelines so as to accurately
specify CAD risk in various ethnic populations. None
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